Paper Details

  1. Home
  2. Paper Details

Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age.

Author: , BamfiFrancesco, CrovariPietro, DenticoPietro, GabuttiGiovanni, HabermehlPeter, KnufMarkus, SchuermanLode, SonciniRenato, ZeppFred

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A combined vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (Hib) was compared to separate vaccines. The combined vaccine was immunogenic and well-tolerated, suggesting that it is a feasible alternative to the separate vaccines.
Paper Details　
Original Abstract of the Article :
A combined DTPa-HBV-IPV/Hib vaccine containing diphtheria (D), tetanus (T), acellular pertussis (Pa), hepatitis B (HBV) and types 1, 2 and 3 inactivated polioviruses (IPV) extemporaneously mixed with a conjugated Haemophilus influenzae type b (Hib) vaccine (Group 1) was compared to the DTPa-HBV-IPV ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15370670

データ提供：米国国立医学図書館（NLM）

Exploring the Efficacy and Safety of a Hexavalent Vaccine

Protecting children from preventable diseases is a cornerstone of public health. This study evaluates the immunogenicity and reactogenicity of a hexavalent combination vaccine containing diphtheria (D), tetanus (T), acellular pertussis (Pa), hepatitis B (HBV), inactivated polioviruses (IPV), and Haemophilus influenzae type b (Hib) vaccine. It compares the effectiveness of administering the vaccine as a single injection versus two separate injections, exploring the optimal vaccination strategy.

The Hexavalent Vaccine: A Promising Option

The study demonstrates that the hexavalent combination vaccine, administered as a single injection, is both immunogenic and well-tolerated, providing comparable immune responses to the separate administration of the vaccines. This finding supports the feasibility of using a hexavalent vaccine as a convenient and effective alternative to separate injections, streamlining the vaccination process for children.

Vaccinating Children: A Crucial Step Towards a Healthier Future

This research provides valuable insights into the efficacy and safety of a hexavalent combination vaccine, highlighting its potential as a valuable tool for protecting children from preventable diseases. By simplifying the vaccination schedule, this vaccine could contribute to improved immunization rates and better public health outcomes. This research is like finding a hidden oasis in the vast desert of vaccine development, offering a promising solution for safeguarding children's health.

Dr.Camel's Conclusion

This study is a beacon of hope in the desert of vaccine research. It demonstrates the efficacy and safety of a hexavalent combination vaccine, offering a convenient and effective way to protect children from a range of preventable diseases. This research is like finding a hidden spring of knowledge, paving the way for healthier and brighter futures for children worldwide.

Date :
  1. Date Completed 2004-10-26
  2. Date Revised 2012-11-15
Further Info :

Pubmed ID

15370670

DOI: Digital Object Identifier

9CDUBWM3VYH14T7U

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.